A Phase I Multicenter Study To Assess The Safety, Tolerability, And Immunogenicity Of Mrna-4157 Alone In Patients With Resected Solid Tumors And In Combination With Pembrolizumab In Patients With Unresectable Solid Tumors.
JOURNAL OF CLINICAL ONCOLOGY(2019)
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要